TY - JOUR
T1 - INNV-25. ASSESSING SLEEP AND CIRCADIAN RHYTHMS IN PRIMARY BRAIN TUMORS PATIENTS: AN OBSERVATIONAL STUDY
AU - Wollet, Alex
AU - Leeper, Heather
AU - Vera, Elizabeth
AU - Mentges, Kelly
AU - King, Amanda
AU - Rogers, James
AU - Sass, Dilorom (Delia)
AU - Acquaye, Alvina
AU - Adegbesan, Kendra
AU - Boris, Lisa
AU - Burton, Eric
AU - Celiku, Orieta
AU - Chambers, Claudia
AU - Choi, Anna
AU - Christ, Alexa
AU - De Le Minyety, Julianie Cruz
AU - Evans, Karen
AU - Grajkowska, Ewa
AU - Komlodi-Pasztor, Edina
AU - Levine, Jason
AU - Lindsley, Matthew
AU - Lollo, Nicole
AU - Mendoza, Tito
AU - Miller, Hope
AU - Panzer, Marissa
AU - Penas-Prado, Marta
AU - Pillai, Valentina
AU - Polskin, Lily
AU - Reyes, Jennifer
AU - Roche, Kayla
AU - Sahebjam, Solmaz
AU - Stockdill, Macy
AU - Theeler, Brett
AU - Wall, Kathleen
AU - Wu, Jing
AU - Gilbert, Mark
AU - Armstrong, Terri
AU - Shuboni-Mulligan, Dorela
PY - 2022/12
Y1 - 2022/12
N2 - Sleep-wake disturbances are among the most common and severe symptoms in primary brain tumor (PBT) patients. Currently, no studies have quantified their physiological sleep measurements or compared these assessments to established patient reported outcome measures (PROs). Smart wearable devices, such as Fitbits, continuously monitor patient behaviors at home and provide detailed physiological measurements of sleep, activity, and heart rate. We hypothesized that smart wearable devices can accurately determine physiological sleep disturbances and circadian disruptions and will complement established PROs in a PBT patient population. This observational, cross-sectional trial monitors sleep and circadian rhythm variables using Fitbit smart wearable devices worn for 1 month. Additionally, participants will answer PROs questionnaires (PROMIS Sleep Disturbance and Sleep Related Impairment-Short Forms, Sleep Hygiene Index, Morningness-Eveningness questionnaire, and Consensus Sleep Diary) at study entry and during the last week on-study. The present study is a planned interim analysis of 54 patients to assess feasibility, including evaluation of enrollment, attrition, study parameter completion and data missingness. 73 PBT patients were screened and approached. Of these patients, 54 (74%) were enrolled on study and 19 (26%) declined participation (8 lacked interest, 3 discomfort wearing watches, 3 lacked smart phone, 2 unable to wear device at work, 2 unable to attend consent calls, 1 pregnancy and 1 cognitive complication). The accrued patients were 56% male, 56%³ 50 years of age, and 81% had a KPS³ 90. Patients represented different stages of treatment: 6% of patients were newly diagnosed, 24% on active treatment (11% 1st recurrence, 13% 2nd recurrence), and 70% were on imaging surveillance. Feasibility was confirmed as there were no deviations reported and 100% of PROs and study timepoints completed. Quantified Fitbit data including percent time worn and physiologic sleep parameters will be reported. Study enrollment for efficacy measures continues.
AB - Sleep-wake disturbances are among the most common and severe symptoms in primary brain tumor (PBT) patients. Currently, no studies have quantified their physiological sleep measurements or compared these assessments to established patient reported outcome measures (PROs). Smart wearable devices, such as Fitbits, continuously monitor patient behaviors at home and provide detailed physiological measurements of sleep, activity, and heart rate. We hypothesized that smart wearable devices can accurately determine physiological sleep disturbances and circadian disruptions and will complement established PROs in a PBT patient population. This observational, cross-sectional trial monitors sleep and circadian rhythm variables using Fitbit smart wearable devices worn for 1 month. Additionally, participants will answer PROs questionnaires (PROMIS Sleep Disturbance and Sleep Related Impairment-Short Forms, Sleep Hygiene Index, Morningness-Eveningness questionnaire, and Consensus Sleep Diary) at study entry and during the last week on-study. The present study is a planned interim analysis of 54 patients to assess feasibility, including evaluation of enrollment, attrition, study parameter completion and data missingness. 73 PBT patients were screened and approached. Of these patients, 54 (74%) were enrolled on study and 19 (26%) declined participation (8 lacked interest, 3 discomfort wearing watches, 3 lacked smart phone, 2 unable to wear device at work, 2 unable to attend consent calls, 1 pregnancy and 1 cognitive complication). The accrued patients were 56% male, 56%³ 50 years of age, and 81% had a KPS³ 90. Patients represented different stages of treatment: 6% of patients were newly diagnosed, 24% on active treatment (11% 1st recurrence, 13% 2nd recurrence), and 70% were on imaging surveillance. Feasibility was confirmed as there were no deviations reported and 100% of PROs and study timepoints completed. Quantified Fitbit data including percent time worn and physiologic sleep parameters will be reported. Study enrollment for efficacy measures continues.
UR - https://www.mendeley.com/catalogue/ff6c050b-720f-3295-9a6f-5897905205cb/
U2 - 10.1093/neuonc/noac209.565
DO - 10.1093/neuonc/noac209.565
M3 - Article
SN - 1522-8517
VL - 24
SP - vii146-vii147
JO - Neuro-Oncology
JF - Neuro-Oncology
IS - Supplement_7
ER -